IRF3 and Hepatitis: Thus, the TLR3/4-TBK1-IRF3-IL-33 signaling pathway activation by HBV plus carcinogen is a mechanism that explains hepatitis and HCC risk associated with HBV infection, which can be blocked by statin to suppress hepatitis and HCC.